UK signs deal with Pfizer/BioNTech for 35 million vaccines

The UK has signed a deal with Pfizer/BioNTech for 35 million vaccines. The doses will be delivered from the second half of 2022.

The UK has agreed a contract for 35 million more doses of the Pfizer/BioNTech vaccine, to be delivered from the second half of next year.

The government, through the Vaccine Taskforce, is putting in place preparations to future-proof the country from the threat of Covid-19 and its variants through safe and effective vaccines, as the UK’s world-renowned vaccination programme continues to protect the population.

These include robust plans for ensuring the country remains ahead of the virus for years to come and for any future booster programmes, as well as working to make the UK a global centre of excellence for the next generation of vaccines.

The Vaccine Taskforce has contracts in place with multiple vaccine manufacturers.

Health and Social Care Secretary Sajid Javid said, “The UK’s phenomenal vaccination programme is providing tens of millions of people with protection from Covid-19, saving 95,200 lives and preventing 82,100 hospitalisations in the over 65s in England alone.

“While we continue to build this wall of defence from Covid-19, it’s also vital we do everything we can to protect the country for the future too – whether that’s from the virus as we know it or new variants.

“I am pleased we’ve reached this agreement with Pfizer for more doses as part of our robust preparations to future-proof our vaccine programme, ensuring we have plans in place to keep the nation safe for years to come,” he added on August 23.

Thank you for taking the time to read this article, please remember to come back and check The Euro Weekly News website for all your up-to-date local and international news stories and follow us on Facebook and Instagram.

Thank you for taking the time to read this article, please remember to come back and check The Euro Weekly News website for all your up-to-date local and international news stories and follow us on Facebook and Instagram.